USPH

US Physical TherapyF

NYSE / Health Care Equipment & Services

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$72.00

+16.4% vs current

Most likely

Base case

50%

Probability

Target price

$63.00

+1.8% vs current

B-

Bear case

25%

Probability

Target price

$52.00

-16.0% vs current

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

Tone is mixed-to-negative after earnings. Checked company filings support record revenue and reaffirmed guidance, but trusted secondary coverage said Q1 adjusted EPS of $0.46 missed a $0.55 consensus and revenue of $198.3 million missed roughly $203.5 million. MarketBeat search coverage indicated the stock traded near $62.18 on May 7, about 15.6% below the pre-print level, and live price data on May 8 showed only a partial stabilization around $59.3. No robust post-print analyst target-revision set was available in checked sources by May 8, which keeps this as a cautious monitoring view rather than a conviction rebound call.

RankAlpha Sentiment Codex - 2026-05-08

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-31catalystPost-earnings digestion after Q1 miss but guidance reaffirmationMedium impact

Q1 net revenue rose 7.9% to $198.3 million, adjusted operating results per share were $0.46, and management reaffirmed full-year 2026 adjusted EBITDA guidance of $102 million to $106 million; the near-term debate is whether the earnings miss is treated as temporary while hospital-alliance ramp begins in May and 2H execution benefits are tested [#8-K-2026-05-06].

2026-09-30eventHospital-alliance ramp and acquisition integration through 2H 2026High impact

Management said two previously announced strategic hospital alliances should be accretive to revenue, EBITDA and margins, with phased ramp-up beginning in May 2026; upon full integration, USPH estimated at least $6 million of annualized EBITDA impact from the Metro clinics and at least $1.3 million from the second subsidiary partner affiliation [#8-K-2026-05-06].

2026-12-31catalystOperational efficiency initiatives and balance-sheet capacityHigh impact

Management highlighted semi-virtualized front desk processes, ambient-listening documentation tools, remote therapeutic monitoring, and cash-pay program expansion as 2H margin and productivity levers, while the new $450 million facility extends capital for growth; execution must offset recent physical-therapy margin pressure and higher borrowings [#8-K-2026-05-06] [#10-Q-2026-05-08].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology